Multiple Myeloma
MLN9708 Plus Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (2606)
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma; Status: Recruiting; Study ID: NCT01564537
A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma; Status: Recruiting; Study ID: NCT01503242
A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma; Status: Recruiting; Study ID: NCT01208662
A Phase 1/2 Study Of Arry-520 In Patients With Relapsed Or Refractory Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma; Status: Recruiting; Study ID: NCT00821249
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone with or without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma; Status: Recruiting; Study ID: NCT01335399
A Multi-Center Phase I, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Investigator: William Bensinger, MD; Conditions: Multiple Myeloma; Status: Recruiting; Study ID: NCT01464034
A Phase 1b, Open-label, Multicenter Study of (BMS-936564) in Combination With Lenalidomide (Revlimid) Plus Low-dose Dexamethasone, or With Bortezomib (Velcade) Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Investigator: Pamela Becker, MD, PhD; Conditions: Multiple Myeloma; Status: Recruiting; Study ID: NCT01359657
A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone Prior to Autologous Stem Cell Transplant in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma
Investigator: Bill Bensinger, MD; Conditions: Multiple Myeloma; Status: Recruiting; Study ID: NCT01660750
Join Us On